ESGAR takes stance on liver MR, liver-specific contrast

The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) is recommending that liver-specific contrast agents be used in liver MRI procedures.

In other recommendations included in its new consensus statement on liver MRI and clinical use of liver-specific contrast agents, ESGAR noted the hepatobiliary phase improves the detection and characterization of hepatocellular lesions and also that liver-specific contrast agents can improve the detection of hepatocellular carcinoma (HCC).

The consensus statement, which was published online on 21 July in European Radiology, is available for open access here.

Page 1 of 138
Next Page